Late Consequences of Acute Coronary Syndromes: Global Registry of Acute Coronary Events (GRACE) Follow-up
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Authors
Alnasser, Sami M.A.Huang, Wei
Gore, Joel M.
Steg, Phillippe Gabriel
Eagle, Kim A.
Anderson, Frederick A. Jr.
Fox, Keith A.
Gurfinkel, Enrique
Brieger, David
Klein, Werner
van de Werf, Frans
Avezum, Alvaro
Montalescot, Gilles
Gulba, Dietrich C.
Budaj, Andrzej
Lopez-Sendon, Jose
Granger, Christopher B.
Kennelly, Brian M.
Goldberg, Robert J.
Fleming, Emily
Goodman, Shaun G.
UMass Chan Affiliations
Department of Quantitative Health Sciences, Division of Epidemiology of Chronic Diseases and Vulnerable PopulationsCenter for Outcomes Research
Department of Medicine, Division of Cardiovascular Medicine
Document Type
Journal ArticlePublication Date
2015-07-01
Metadata
Show full item recordAbstract
PURPOSE: Short-term outcomes have been well characterized in acute coronary syndromes; however, longer-term follow-up for the entire spectrum of these patients, including ST-segment-elevation myocardial infarction, non-ST-segment-elevation myocardial infarction, and unstable angina, is more limited. Therefore, we describe the longer-term outcomes, procedures, and medication use in Global Registry of Acute Coronary Events (GRACE) hospital survivors undergoing 6-month and 2-year follow-up, and the performance of the discharge GRACE risk score in predicting 2-year mortality. METHODS: Between 1999 and 2007, 70,395 patients with a suspected acute coronary syndrome were enrolled. In 2004, 2-year prospective follow-up was undertaken in those with a discharge acute coronary syndrome diagnosis in 57 sites. RESULTS: From 2004 to 2007, 19,122 (87.2%) patients underwent follow-up; by 2 years postdischarge, 14.3% underwent angiography, 8.7% percutaneous coronary intervention, 2.0% coronary bypass surgery, and 24.2% were re-hospitalized. In patients with 2-year follow-up, acetylsalicylic acid (88.7%), beta-blocker (80.4%), renin-angiotensin system inhibitor (69.8%), and statin (80.2%) therapy was used. Heart failure occurred in 6.3%, (re)infarction in 4.4%, and death in 7.1%. Discharge-to-6-month GRACE risk score was highly predictive of all-cause mortality at 2 years (c-statistic 0.80). CONCLUSION: In this large multinational cohort of acute coronary syndrome patients, there were important later adverse consequences, including frequent morbidity and mortality. These findings were seen in the context of additional coronary procedures and despite continued use of evidence-based therapies in a high proportion of patients. The discriminative accuracy of the GRACE risk score in hospital survivors for predicting longer-term mortality was maintained.Source
Am J Med. 2015 Jul;128(7):766-75. doi: 10.1016/j.amjmed.2014.12.007. Epub 2014 Dec 29. Link to article on publisher's siteDOI
10.1016/j.amjmed.2014.12.007Permanent Link to this Item
http://hdl.handle.net/20.500.14038/30362PubMed ID
25554379Related Resources
Link to Article in PubMedae974a485f413a2113503eed53cd6c53
10.1016/j.amjmed.2014.12.007